Optimization of combined temozolomide and peptide receptor radionuclide therapy (PRRT) in mice after multimodality molecular imaging studies

Background: Successful treatments of patients with somatostatin receptor (SSTR)-overexpressing neuroendocrine tumours (NET) comprise somatostatin-analogue lutetium-177-labelled octreotate (177Lu-TATE) treatment, also referred to as peptide receptor radionuclide therapy (PRRT), and temozolomide (TMZ) treatment. Their combination might result in additive effects. Using MRI and SPECT/CT, we studied tumour characteristics and therapeutic responses after different (combined) administration schemes in a murine tumour model in order to identify the optimal treatment schedule for PRRT plus TMZ. Methods: We performed molecular imaging studies in mice bearing SSTR-expressing H69 (humane small cell lung cancer) tumours after single intravenous (i.v.) administration of 30 MBq 177Lu-TATE or

Peptide receptor radionuclide therapy using radiolabeled somatostatin analogs: Focus on future developments

Peptide receptor radionuclide therapy (PRRT) has been shown to be an effective treatment for neuroendocrine tumors (NETs) if curative surgery is not an option. A majority of NETs abundantly express somatostatin receptors. Consequently, following administration of somatostatin (SST) analogs labeled with γ-emitting radionuclides, these tumors can be imaged for diagnosis, staging or follow-up purposes. Furthermore, when β-emitting radionuclides are used, radiolabeled peptides (radiopeptides) can also be used for the treatment for NET patients. Even though excellent results have been achieved with PRRT, complete responses are still rare, which means that there is room for improvement. In this review, we highlight some of the directions currently under investigation in pilot clinical studies or in preclinical development to achieve this goal. Although randomized clinical trials are still lacking, early studies have shown that tumor response might be improved by a

Gaia white dwarfs within 40 pc – III. Spectroscopic observations of new candidates in the Southern hemisphere

We present a spectroscopic survey of 248 white dwarf candidates within 40 pc of the Sun; of these 244 are in the Southern hemisphere. Observations were performed mostly with the Very Large Telescope (X-Shooter) and Southern Astrophysical Research Telescope. Almost all candidates were selected from Gaia Data Release 3 (DR3). We find a total of 246 confirmed white dwarfs, 209 of which had no previously published spectra, and two main-sequence star contaminants. Of these, 100 white dwarfs display hydrogen Balmer lines, 69 have featureless spectra, and two show only neutral helium lines. Additionally, 14 white dwarfs display traces of carbon, while 37 have traces of other elements that are heavier than helium. We observe 35 magnetic white dwarfs through the detection of Zeeman splitting of their hydrogen Balmer or metal spectral lines. High spectroscopic completeness (> 97 per cent) has now been reached, such that we have 1058 confirmed Gaia DR3 white dwarfs out of 1083 candidates within 40 pc of the Sun at all declinations

Search for high-energy neutrinos from gravitational wave event GW151226 and candidate LVT151012 with ANTARES and IceCube

The Advanced LIGO observatories detected gravitational waves from two binary black hole mergers during their first observation run (O1). We present a high-energy neutrino follow-up search for the second gravitational wave event, GW151226, as well as for gravitational wave candidate LVT151012. We find two and four neutrino candidates detected by IceCube, and one and zero detected by Antares, within ±500 s around the respective gravitational wave signals, consistent with the expected background rate. None of these neutrino candidates are found to be directionally coincident with GW151226 or LVT151012. We use nondetection to constrain isotropic-equivalent high-energy neutrino emission from GW151226, adopting the GW event's 3D localization, to less than 2×1051-2×1054 erg. © 2017 American Physical Society